PUBLISHER: Market Research Future | PRODUCT CODE: 1630514
PUBLISHER: Market Research Future | PRODUCT CODE: 1630514
Blood Coagulation Testing Market Research Report Information by Product (Consumables and Instruments), by Application (Acquired Bleeding Disorders and Inherited Bleeding Disorders), by Test Type (Prothrombin Time Testing, Activated Partial Thromboplastin Time (aPTT) Testing, Fibrinogen Testing, Activated Clotting Time Testing, Platelet Function Tests, and Others), by End User (Hospitals and Clinics, Diagnostic Centers, Ambulatory Care Centers, and Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World Industry Forecast to 2032
The Blood Coagulation Testing Market was valued at USD 4.51 billion in 2023. The Blood Coagulation Testing Market is expected to increase from USD 4.81 billion in 2024 to USD 7.84 billion by 2032, with a compound annual growth rate (CAGR) of 6.31% over the forecast period (2024-2032).
The rising prevalence of blood-acquired bleeding disorders, as well as increased product launches by market players in the blood coagulation testing market, are the primary drivers of growth. However, voluntary product recalls by market participants, as well as the high cost of coagulation analyzers, are projected to impede worldwide market expansion. Nonetheless, favorable government initiatives related to bleeding disorders and an increasing geriatric population around the world are expected to generate profitable potential for the industry.
The rising prevalence of both acquired and hereditary bleeding diseases, such as hemophilia, von Willebrand Disease, and other related ailments, is driving the growth of the blood coagulation testing market.
Market Segment insights
Consumables and instruments make up the product sector of the Blood Coagulation Testing Market.
The Blood Coagulation Testing Market is segmented by application, which includes both acquired and inherited bleeding diseases.
The Blood Coagulation Testing Market is divided into test types, which include prothrombin time testing, activated partial thromboplastin time (aPTT) testing, fibrinogen testing, activated clotting time testing, platelet function tests, and others.
End-user segments in the Blood Coagulation Testing Market comprise hospitals and clinics, diagnostic centers, ambulatory care centers, and others.
Regional insights
The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American Blood Coagulation Testing market is expanding rapidly, owing to the rising prevalence of coagulation diseases as well as technological and innovative improvements. Furthermore, the region's well-established healthcare infrastructure, technological advancements, and favorable regulatory environment all contribute to the market's growth.
The European Blood Coagulation Testing market accounted for the second-largest market share, owing to strong healthcare infrastructure and supported government health initiatives and financing. Furthermore, the Germany Blood Coagulation Testing supplier is said to have the greatest market share, while the France Blood Coagulation Testing provider is expected to be the fastest growing market in Europe.
The Asia-Pacific Blood Coagulation Testing market is predicted to develop the fastest from 2023 to 2032, owing to increased public awareness of health management and early diagnosis, as well as favorable reimbursement policies for coagulation tests. Furthermore, China Blood Coagulation Testing accounted for the greatest market share, while India Blood Coagulation Testing is expected to be the fastest expanding market in the Asia Pacific region.
Hoffmann-La Roche Ltd., Abbott, Siemens Healthcare, Thermo Fisher Scientific Inc., Sysmex Corporation, Werfen, HemoSonics, LLC, Micropoint Biotechnologies Co., Ltd., Helena Laboratories, and Meril Life Sciences Pvt. Ltd. are among the key players in the Blood Coagulation Testing market.